140 related articles for article (PubMed ID: 26935234)
1. A (relatively) risky business: the link between prostatic radiotherapy and second malignancies.
Eyler CE; Zietman AL
BMJ; 2016 Mar; 352():i1073. PubMed ID: 26935234
[TBL] [Abstract][Full Text] [Related]
2. Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up.
Liauw SL; Sylvester JE; Morris CG; Blasko JC; Grimm PD
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):669-73. PubMed ID: 16887293
[TBL] [Abstract][Full Text] [Related]
3. Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis.
Wallis CJ; Mahar AL; Choo R; Herschorn S; Kodama RT; Shah PS; Danjoux C; Narod SA; Nam RK
BMJ; 2016 Mar; 352():i851. PubMed ID: 26936410
[TBL] [Abstract][Full Text] [Related]
4. Prostate radiotherapy is associated with second cancers in many organs, not just the colorectum.
Brenner DJ; Hall EJ; Curtis RE; Ron E
Gastroenterology; 2005 Aug; 129(2):773-4; author reply 774-5. PubMed ID: 16083746
[No Abstract] [Full Text] [Related]
5. Modelling second malignancy risks from low dose rate and high dose rate brachytherapy as monotherapy for localised prostate cancer.
Murray L; Mason J; Henry AM; Hoskin P; Siebert FA; Venselaar J; Bownes P;
Radiother Oncol; 2016 Aug; 120(2):293-9. PubMed ID: 27370205
[TBL] [Abstract][Full Text] [Related]
6. The risk of second malignancies after
Fernandez Ots A; Browne L; Chin YS; Malouf D; Wong K; Bucci J
Brachytherapy; 2016; 15(6):752-759. PubMed ID: 27475483
[TBL] [Abstract][Full Text] [Related]
7. Radical cystectomy in patients previously treated for localized prostate cancer.
Jayram G; Katz MH; Steinberg GD
Urology; 2010 Dec; 76(6):1430-3. PubMed ID: 20381130
[TBL] [Abstract][Full Text] [Related]
8. [Two cases of second bladder cancer after radiotherapy for prostate cancer].
Numata K; Azuma K; Hashine K; Sumiyoshi Y
Nihon Hinyokika Gakkai Zasshi; 2005 Mar; 96(3):466-9. PubMed ID: 15828265
[TBL] [Abstract][Full Text] [Related]
9. Secondary malignancies from prostate cancer radiation treatment: a risk analysis of the influence of target margins and fractionation patterns.
Daşu A; Toma-Daşu I; Franzén L; Widmark A; Nilsson P
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):738-46. PubMed ID: 20472345
[TBL] [Abstract][Full Text] [Related]
10. Incidence of second malignancies in prostate cancer patients treated with low-dose-rate brachytherapy and radical prostatectomy.
Hamilton SN; Tyldesley S; Hamm J; Jiang WN; Keyes M; Pickles T; Lapointe V; Kahnamelli A; McKenzie M; Miller S; Morris WJ
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):934-41. PubMed ID: 25240272
[TBL] [Abstract][Full Text] [Related]
11. Second primary cancers occurring after I-125 brachytherapy as monotherapy for early prostate cancer.
Musunuru H; Mason M; Murray L; Al-Qaisieh B; Bownes P; Smith J; Franks K; Carey B; Bottomley D; Henry AM
Clin Oncol (R Coll Radiol); 2014 Apr; 26(4):210-5. PubMed ID: 24507938
[TBL] [Abstract][Full Text] [Related]
12. Risk of second cancer following radiotherapy for prostate cancer: a population-based analysis.
Hegemann NS; Schlesinger-Raab A; Ganswindt U; Hörl C; Combs SE; Hölzel D; Gschwend JE; Stief C; Belka C; Engel J
Radiat Oncol; 2017 Jan; 12(1):2. PubMed ID: 28049538
[TBL] [Abstract][Full Text] [Related]
13. Contemporary issues in radiotherapy for clinically localized prostate cancer.
Khor R; Williams S
Hematol Oncol Clin North Am; 2013 Dec; 27(6):1137-62, vii. PubMed ID: 24188256
[TBL] [Abstract][Full Text] [Related]
14. Acute myelogenous leukemia after exposure to strontium-89 for the treatment of adenocarcinoma of the prostate.
Welsh JS; Howard SP
Cancer; 2000 Jul; 89(1):226-7. PubMed ID: 10897031
[No Abstract] [Full Text] [Related]
15. Examining the co-occurrence of bladder and prostate cancer: a worthwhile investigation?
Kellen E; Zeegers MP; Joniau S; Buntinx F
Future Oncol; 2007 Oct; 3(5):515-9. PubMed ID: 17927517
[TBL] [Abstract][Full Text] [Related]
16. Genitourinary cancers.
Krueger H; McLean D; Williams D
Prog Exp Tumor Res; 2008; 40():92-101. PubMed ID: 18802392
[No Abstract] [Full Text] [Related]
17. The characteristics of bladder cancer after radiotherapy for prostate cancer.
Abern MR; Dude AM; Tsivian M; Coogan CL
Urol Oncol; 2013 Nov; 31(8):1628-34. PubMed ID: 22575239
[TBL] [Abstract][Full Text] [Related]
18. Commentary on "secondary cancers after intensity-modulated radiotherapy, brachytherapy, and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention." Zelefsky MJ, Pei X, Teslova T, Kuk D, Magsanoc JM, Kollmeier M, Cox B, Zhang Z. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY.: BJU Int 2012;110:1696-701. doi: 10.1111/j.1464-410X.2012.11385.x. [Epub 2012 Aug 13].
Gottschalk A
Urol Oncol; 2014 Feb; 32(2):209. PubMed ID: 24445290
[TBL] [Abstract][Full Text] [Related]
19. Secondary cancers after intensity-modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention.
Zelefsky MJ; Pei X; Teslova T; Kuk D; Magsanoc JM; Kollmeier M; Cox B; Zhang Z
BJU Int; 2012 Dec; 110(11):1696-701. PubMed ID: 22889401
[TBL] [Abstract][Full Text] [Related]
20. Modelling of organ-specific radiation-induced secondary cancer risks following particle therapy.
Stokkevåg CH; Fukahori M; Nomiya T; Matsufuji N; Engeseth GM; Hysing LB; Ytre-Hauge KS; Rørvik E; Szostak A; Muren LP
Radiother Oncol; 2016 Aug; 120(2):300-6. PubMed ID: 27424291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
